Human full-length osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo

Journal of Vascular Research

Volumn 47, Issue 3, 2010, Pages 252-261

  Candido, Riccardo ^a   Toffoli, Barbara ^d   Corallini, Federica ^b   Bernardi, Stella ^c   Zella, Davide ^e   Voltan, Rebecca ^c   Grill, Vittorio ^b   Celeghini, Claudio ^b   Fabris, Bruno ^c  

^a ASS 1 Triestina   (Italy)

^b Department of Biomedicine ^*  (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

^d UNIVERSITY OF FERRARA   (Italy)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Apolipoprotein E null mice; Atherosclerosis; Cell proliferation; Osteoprotegerin; Vascular smooth muscle cells

Indexed keywords

ANGIOPOIETIN 2; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BODY WEIGHT; CELL CULTURE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MACROPHAGE MIGRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; STREPTOZOCIN DIABETES; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR SMOOTH MUSCLE;

ANGIOPOIETIN-2; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELL PROLIFERATION; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; DISEASE MODELS, ANIMAL; HUMANS; INJECTIONS, INTRAPERITONEAL; MICE; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OSTEOPROTEGERIN; RATS; RECOMBINANT PROTEINS; RNA, MESSENGER;

EID: 70449515405     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000257339     Document Type: Article

References (47)

1. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Ren-shaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ: Oste oproteger i n: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-319.
2. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ: Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteo-protegerin ligand. Proc Natl Acad Sci USA 1999; 96:3540-3545.
3. Zauli G, Secchiero P: The role of the TRAIL\TRAIL-receptors system in hematopoiesis and endothelial cell biology. Cytokine Grow th Fact Rev 2006; 17: 245-247.
4. Zauli G, Rimondi E, Nicolin V, Melloni E, Celeghini C, Secchiero P: TNF-related apop-tosis inducing ligand (TRAIL) blocks osteo-clastic differentiation induced by RANKL + M-CSF. Blood 2004; 104:2044-2050.
5. Chamoux E, Houde N, L'Eriger K, Roux S: Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway. J Cell Physiol 2008; 216:536-542.
6. Kip1 accumulation in pre-osteoclast precursors. J Cell Physiol 2008; 214: 117-125.
7. Vitovski S, Phillips JS, Sayers J, Croucher PI: Investigating the interaction between osteo-protegerin and RANKL or TRAIL: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J Biol Chem 2007; 282:31601-31609.
8. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, Nishizawa Y: Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002; 106:1192-1194.
9. Schoppet M, Sattler AM, Schaefer JR, Her-zum M, Maisch B, Hofbauer LC: Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003; 88: 1024-1028.
10. Kiechl S, Schett G, Wenning G, Redlich K, Oberhoolenser M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J: Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004; 109:2175-2180.
11. Ueland T, Jemtland R, Godang K, Kjekshus J, Hognestad A, Omland T, Squire IB, Gulles-tad L, Bollerslev J, Dickstein K, Aukrust P: Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 2004; 44:1970-1976.
12. Ueland T, Yndestad A, Øie E, Florholmen G, Halvorsen B, Frøland SS, Simonsen S, Chris-tensen G, Gullestad L, Aukrust P: Dysregu-lated osteoprotegerin\RANK ligand\RANK axis in clinical and experimental heart failure. Circulation 2005; 111: 2461-2468.
13. Moran CS, McCann M, Karan M, Normal P, Ketheesan N, Golledge J: Association of os-teoprotegerin with human abdominal aortic aneurysm progression. Circulation 2005; 111: 3119-3125.
14. Secchiero P, Corallini F, Pandolfi A, Consoli A, Candido R, Fabris B, Celeghini C, Capi-tani S, Zauli G: An increased osteoproteger-in (OPG) serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol 2006; 169:2236-2244.
15. Shin JY, Shin YG, Chun CH: Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Diabetes Care 2006; 29:1664-1666.
16. Abedin M, Omland T, Ueland T, Khera A, Aukrust P, Murphy SA, Jain T, Gruntmanis U, McGuire DK, de Lemos JA: Relation of os-teoprotegerin to coronary calcium and aortic plaque. Am J Cardiol 2007; 99:513-518.
17. Helske S, Kovanen PT, Lindstedt KA, Salme-la K, Lommi J, Turto H, Werkkala K, Kupari M: Increased circulating concentrations and augmented myocardial extraction of osteo-protegerin in heart failure due to left ventricular pressure overload. Eur J Heart Fail 2007; 28: 1894-1903.
18. Avignon A, Sultan A, Piot C, Mariano-Gou-lart D, Thuan Dit Dieudonné JF, Cristol JP, Dupuy AM: Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care 2007; 30: 2934-2939.
19. Omland T, Ueland T, Jansson AM, Persson A, Karlsson T, Smith C, Herlitz J, Aukrust P, Hartford M, Caidahl K: Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 2008; 51: 627-633.
20. Jorsal A, Tarnow L, Flyvbjerg A, Parving HH, Rossing P, Rasmussen LM: Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetologia 2008; 51: 2100-2107.
21. Nybo M, Rasmussen L: The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. Eur J Endocrinol 2008; 159: 603-608.
22. Zauli G, Corallini F, Bossi F, Fischetti F, Du-rigutto P, Celeghini C, Tedesco F, Secchiero P: Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood 2007; 110:536-543.
23. Mangan SH, Campenhout AV, Rush C, Golledge J: Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-a associated with induction of angiopoietin-2. Cardiovasc Res 2007; 76: 494-505.
24. Libby P: Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
25. Lawrie A, Waterman E, Southwood M, Evans D, Suntharalingam J, Francis S, Cross-man D, Croucher P, Morrell N, Newman C: Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension. Am J Pathol 2008; 172:256-264.
26. Candido R, Allen TJ, Lassila M, Cao Z, Thal-las V, Cooper ME, Jandeleit-Dahm KA: Irbe-sartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation 2004; 109:1536-1542.
27. Secchiero P, Zerbinati C, Rimondi E, Corallini F, Milani D, Grill V, Forti G, Capitani S, Zauli G: TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 2004; 61: 1965-1974.
28. Borgatti P, Zauli G, Colamussi ML, Gibellini D, Previati M, Cantley L, Capitani S: Extracellular HIV-1 Tat protein activates phos-phatidylinositol 3-and Akt\PKB kinases in CD4+ T lymphoblastoid Jurkat cells. Eur J Immunol 1997; 27: 2805-2811.
29. Secchiero P, Candido R, Corallini F, Zacchi-gna S, Toffoli B, Rimondi E, Fabris B, Giacca M, Zauli G: Systemic TRAIL delivery shows anti-atherosclerotic activity in apoE-null diabetic mice. Circulation 2006; 114: 1522-1530.
30. Standal T, Seidel C, Hjertner O, Plesner T, Sanderson RD, Waage A, Borset M, Sundan A: Osteprotegerin is bound, internalized and degraded by multiple myeloma cells. Blood 2002; 100:3002-3007.
31. Fiedler U, Reiss Y, Scharpfenecker M, Grun-ow V, Koidl S, Thurston G, Gale NW, Wit-zenrath M, Rosseau S, Suttorp N, Sobke A, Herrmann M, Preissner KT, Vajkoczy P, Au-gustin HG: Angiopoietin-2 sensitizes endothelial cells to TNF-a and has a crucial role in the induction of inflammation. Nat Med 2006; 12:235-239.
32. Wara AK, Mitsumata M, Yamane T, Kusumi Y, Yoshida Y: Gene expression in endothelial cells and intimal smooth muscle cells in atherosclerosis-prone and atherosclerosis-resistant regions of the human aorta. J Vasc Res 2008; 45:303-313.
33. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS: Osteo-protegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12:1260-1268.
34. Price PA, June HH, Buckley JR, Williamson MK: Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 2001; 21: 1610-1616.
35. -\- mice. Arterioscler Thromb Vasc Biol 2006; 28:2117-2124.
36. Price PA, Faus SA, Williamson MK: Bisphos-phonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 2001; 21:817-824.
37. Olesen P, Ledet T, Rasmussen LM: Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia 2005; 48:561-568.
38. Zhang J, Fu M, Myles D, Zhu X, Du J, Cao X, Chen YE: PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett 2002; 521: 180-184.
39. Nybo M, Rasmussen LM: Osteoprotegerin released from the vascular wall by heparin mainly derives from va scu la r smoot h muscle cells. Atherosclerosis 2008, E-pub ahead of print.
40. Secchiero P, Gonelli A, Carnevale E, Milani D, Pandolfi A, Zella D, Zauli G: TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 2003; 107: 2250-2256.
41. Zauli G, Pandolfi A, Gonelli A, Di Pietro R, Guarnieri S, Ciabat ton i G, Rana R, Vita le M, Secchiero P: TNF-related apoptosis-induc-ing ligand (TRAIL) sequentially up-regu-lates nitric oxide and prostanoid production in primary human endothelial cells. Circ Res 2003; 92:732-740.
42. Secchiero P, Corallini F, di Iasio MG, Gonelli A, Barbarotto E, Zauli G: TRAIL counteracts the proadhesive activity of inf lammatory cy-tokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood 2005; 105: 3413-3419.
43. Schoppet M, Sattler AM, Schaefer JR, Hof-bauer LC: Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis. Atherosclerosis 2006; 184:446-447. (Pubitemid 43049733)
44. Michowitz Y, Goldstein E, Roth A, Afek A, Abashidze A, Ben Gal Y, Keren G, George J: The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis. J Am Coll Cardiol 2005; 45: 1018-1024.
45. Morony S, Tintut Y, Zhang Z, Cattley RC, Van G, Dwyer D, Stolina M, Kostenuik PJ, Demer LL: Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-\-) mice. Circulation 2008; 117:411-420.
46. Kearns AE, Khosla S, Kostenuik P: RANKL and OPG regulation of bone remodeling in hea lth and disease. Endocr Rev 2008; 29: 155-192.
47. Rauch BH, Millette E, Kenagy RD, Daum G, Fischer JW, Clowes AW: Syndecan-4 is required for thrombin-induced migration and proliferation in human vascular smooth muscle cells. J Biol Chem 2005; 280:17507-17511.